Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
53-19-0
Molecular formula
C14H10Cl4
Molecular weight
320 g/mol
Drug class
Adrenocortical cytotoxic and adrenolytic agentsteroidogenesis inhibitor
Mechanism of action
The precise molecular mechanism is not fully understood. Mitotane has selective cytotoxic and adrenolytic effects on adrenal cortical tissue and suppresses steroid synthesis, including cortisol production. It can alter hepatic drug-metabolising enzymes and steroid-binding proteins.
Indications / reported uses
Treatment of patients with inoperable, functional or nonfunctional adrenocortical carcinoma (ACC) under the US LYSODREN indication; requires specialist monitoring of plasma mitotane levels, adrenal function and toxicity
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Mitotane PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Mitotane Permitted Daily Exposure (PDE) report (the Mitotane PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Mitotane Occupational Exposure Limit (OEL) report (the Mitotane OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.